Tests a new drug combination with chemotherapy for extensive-stage small cell lung cancer
Compares a new drug combination with standard treatment in adults with small cell lung cancer.
Plain-language title generated from the registry record
Registry title: A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Key facts
- Where
- Bunkyo-ku, Fukushima, Hamamatsu, Hidaka, Hirakata, Ina-machi, Kanazawa, Kashihara, Kobe, Koto, Kurashiki, Kurume, Matsuyama, Ōsaka-sayama, Sapporo, Sendai, Takatsuki, and Yokohama, JapanSee the 18 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes your lung cancer?
- Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
- Can you look after yourself and are you up and about most of the day?
- Has your cancer spread to the brain?
Source: NCT06646276, who can take part
Where in Japan
- Bunkyo-kuBunkyo-ku, JapanNo longer taking part
- FukushimaFukushima, JapanNo longer taking part
- HamamatsuHamamatsu, JapanNo longer taking part
- HidakaHidaka, JapanNo longer taking part
- HirakataHirakata, JapanNo longer taking part
- Ina-machiIna-machi, JapanNo longer taking part
- KanazawaKanazawa, JapanNo longer taking part
- KashiharaKashihara, JapanNo longer taking part
- KobeKobe, JapanNo longer taking part
- KotoKoto, JapanNo longer taking part
- KurashikiKurashiki, JapanNo longer taking part
- KurumeKurume, JapanNo longer taking part
- MatsuyamaMatsuyama, JapanNo longer taking part
- Ōsaka-sayamaŌsaka-sayama, JapanNo longer taking part
- SapporoSapporo, JapanNo longer taking part
- SendaiSendai, JapanNo longer taking part
- TakatsukiTakatsuki, JapanNo longer taking part
- YokohamaYokohama, JapanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06646276EU 2024-515740-23-00
- Record updated
- 10 November 2026
- Original description
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.Read full original descriptionShow less
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (Atigotatug+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Inclusion: Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC); Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale; Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system.
Exclusion: Participants have already received certain types of treatment for extensive stage small cell lung cancer; Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy; Other protocol-defined Inclusion/Exclusion criteria apply.